Cancers | Free Full-Text | Immune Resistance and EGFR Antagonists in Colorectal Cancer
MET inhibitors for targeted therapy of EGFR TKI-resistant lung cancer | Journal of Hematology & Oncology | Full Text
Liquid biopsy uncovers distinct patterns of DNA methylation and copy number changes in NSCLC patients with different EGFR-TKI resistant mutations | Scientific Reports
Frontiers | Preclinical Models for Acquired Resistance to Third-Generation EGFR Inhibitors in NSCLC: Functional Studies and Drug Combinations Used to Overcome Resistance
Hype or hope – Can combination therapies with third-generation EGFR-TKIs help overcome acquired resistance and improve outcomes in EGFR-mutant advanced/metastatic NSCLC? - ScienceDirect
The mechanism of acquired resistance to epidermal growth factor... | Download Scientific Diagram
MET amplification and epithelial-to-mesenchymal transition exist as parallel resistance mechanisms in erlotinib-resistant, EGFR-mutated, NSCLC HCC827 cells | Oncogenesis
Acquired Resistance to Osimertinib Plus Savolitinib Is Mediated by MET-D1228 and MET-Y1230 Mutations in EGFR-Mutated MET-Amplified Lung Cancer - ScienceDirect
EGFR-TKI resistance promotes immune escape in lung cancer via increased PD-L1 expression | Molecular Cancer | Full Text
Common resistance mechanisms to EGFR TKIs in EGFR-mutated lung... | Download Scientific Diagram
MET amplification causes EGFR-TKI resistance by activating... | Download Scientific Diagram
Cells | Free Full-Text | Mechanism of Resistance to Epidermal Growth Factor Receptor-Tyrosine Kinase Inhibitors and a Potential Treatment Strategy
Cancers | Free Full-Text | MET Amplification as a Resistance Driver to TKI Therapies in Lung Cancer: Clinical Challenges and Opportunities
Mechanisms and management of 3rd‑generation EGFR‑TKI resistance in advanced non‑small cell lung cancer (Review)
Amivantamab: A Potent Novel EGFR/c-MET Bispecific Antibody Therapy for EGFR-mutated Non-small Cell Lung Cancer - touchONCOLOGY
When the MET receptor kicks in to resist targeted therapies | Oncogene
Impact of MET alterations on targeted therapy with EGFR-tyrosine kinase inhibitors for EGFR-mutant lung cancer | Biomarker Research | Full Text
Mechanisms and management of 3rd‑generation EGFR‑TKI resistance in advanced non‑small cell lung cancer (Review)
MET amplification causes EGFR-TKI resistance by activating... | Download Scientific Diagram
Frontiers | A Large Real-World Study on the Effectiveness of the Combined Inhibition of EGFR and MET in EGFR-Mutant Non-Small-Cell Lung Cancer After Development of EGFR-TKI Resistance
Overcoming MET-mediated resistance in oncogene-driven NSCLC - ScienceDirect
